Journals / Acta Orthopaedica et Traumatologica Turcica / 2007 / Cilt: 41 - Sayı: 3

Survival analysis and the effects of prognostic factors in patients treated for osteosarcoma

Osteosarkom nedeniyle tedavi edilen hastalarda sağkalım analizi ve prognostik faktörlerin etkileri

Pages
211–219
DOI
—
🏛️Bibliographic metadata and full text access for this article are provided via DergiPark.
DergiPark Record ↗
✨

AI Summary & Key Takeaways

AI Insight
⚡ TL;DR(Too Long; Didn't Read)

Objectives: We evaluated long-term treatment results of patients with primary osteosarcoma and the effect of prognostic factors on overall survival and disease-free survival.

📌 3 Key Takeaways

🎯
Objective & Hypothesis:Objectives: We evaluated long-term treatment results of patients with primary osteosarcoma and the effect of prognostic factors on overall survival and disease-free survival.
📊
Key Findings & Data:Methods: Between 1995 and 2005, 180 patients (111 males, 69 females; mean age 21±10 years; range 7 to 64 years) were treated for primary osteosarcoma.
💡
Conclusion & Impact:As in every malignant disease, early admission would provide better survival rates.
🔬Design:Research Article
📍Scope:2005 Verileri
⚙️Variables:Hastalıksız sağkalım · Kombine tedavi uygulaması · Osteosarkom

Abstract

Objectives: We evaluated long-term treatment results of patients with primary osteosarcoma and the effect of prognostic factors on overall survival and disease-free survival. Methods: Between 1995 and 2005, 180 patients (111 males, 69 females; mean age 21±10 years; range 7 to 64 years) were treated for primary osteosarcoma. Overall and disease-free survival rates were analyzed for 165 patients with high-grade osteosarcoma with the Kaplan-Meier method. The effects of potential prognostic factors were assessed, including age, gender, localization, tumor size, primary metastasis on presentation, the presence of pathologic fractures, necrosis rate, and infection. All the patients received chemotherapy before and after surgery. The mean follow-up period was 49.7 months (range 6 to 185) months. Results: Sixty-nine patients were below 16 years of age. The most frequent involvement was in the distal femur (47.2%), followed by the proximal tibia (25%). Sixteen patients presented with a pathologic fracture, and 12 patients with metastasis. The median tumor size was 10 cm. The overall fiveand 10-year survival rates were 68% and 60%, and diseasefree survival rates were 50% and 44%, respectively. Only the presence of a pathologic fracture and primary metastasis on presentation were found to affect prognosis. Conclusion: The two conditions, primary metastasis and a pathologic fracture, found as the most important prognostic factors in our study are mainly associated with late presentation. As in every malignant disease, early admission would provide better survival rates.

Özet

Amaç: Primer osteosarkomlu hastaların uzun vadeli tedavi sonuçları ve çeşitli prognostik faktörlerin sağkalım ve hastalıksız sağkalım üzerine etkileri değerlendirildi. Çalışma planı: 1991-2005 yılları arasında primer osteosarkom nedeniyle tedavi edilen 180 hasta (111 erkek, 69 kadın; ort. yaş 21±10; dağılım 7-64) çalışmaya alındı. Yüksek dereceli tümörü olan 165 hastada genel ve hastalıksız sağkalım oranları Kaplan-Meier yöntemiyle hesaplandı. Yaş, cinsiyet, yerleşim yeri, tümör büyüklüğü, başvuruda metastaz varlığı, patolojik kırık, nekroz oranı, enfeksiyon gibi faktörlerin prognoz üzerine etkisi araştırıldı. Cerrahi tedaviden önce ve sonra hastalara kemoterapi uygulandı. Ortalama takip süresi 49.7 ay (dağılım 6-185 ay) idi. Sonuçlar: Altmış dokuz hasta 16 yaşından küçük idi. Tümörler en sık femur distali (%47.2) ve tibia proksimalinde (%25) görüldü. On altı hasta patolojik kırıkla, 12 hasta metastaz ile başvurmuştu. Ortanca tümör büyüklüğü 10 cm idi. Genel sağkalım beş yıl için %68, 10 yıl için %60 olarak belirlendi. Hastalıksız sağkalım beş yıl için %50, 10 yıl için %44 bulundu. İncelenen faktörlerden sadece patolojik kırık ve başvuruda metastaz varlığının prognozu olumsuz etkilediği belirlendi. Çıkarımlar: Çalışmamızda, en önemli prognostik faktörler olarak belirlenen metastazla başvuru ve patolojik kırık oluşumu genellikle geç başvuru ile ilişkilidir. Her türlü habis hastalıkta olduğu gibi osteosarkomda da erken başvurunun sağlanması ile daha yüksek sağkalım oranları elde edilebilir

🔖

Cite This Article

ÖZGER, H., ERALP, L., ATALAR, A. C., TOKER, B., AYAN, İ., KEBUDİ, R., BAĞBEK, S., BAŞARAN, M., AĞAOĞLU, F., DİZDAR, Y., BİLGİÇ, B. (2007). Survival analysis and the effects of prognostic factors in patients treated for osteosarcoma. Acta Orthopaedica et Traumatologica Turcica, Cilt: 41 - Sayı: 3, 211–219. https://ajindex.com/articles/353898

📄 Full Text PDF Viewer

📄

PDF görüntüleyici hazırlanıyor...

References (12)

  1. Link MP, Goorin AM, Miser AW, Green AA, Pratt CB, Belasco JB, et al. The effect of adjuvant chemotherapy on relapse-free survival in patients with osteosarcoma of the extremity. N Engl J Med 1986;314:1600-6
  2. Winkler K, Beron G, Kotz R, Salzer-Kuntschik M, Beck J, Beck W, et al. Neoadjuvant chemotherapy for osteogenic sarcoma: results of a Cooperative German/Austrian study. J Clin Oncol 1984;2:617-24
  3. Bielack SS, Kempf-Bielack B, Delling G, Exner GU, Flege S, Helmke K, et al. Prognostic factors in high-grade osteosarcoma of the extremities or trunk: an analysis of 1,702 patients treated on neoadjuvant cooperative osteosarcoma study group protocols. J Clin Oncol 2002;20:776-90
  4. Bacci G, Ferrari S, Bertoni F, Ruggieri P, Picci P, Longhi A, et al. Long-term outcome for patients with nonmetastatic osteosarcoma of the extremity treated at the Istituto Ortopedico Rizzoli according to the Istituto Ortopedico Rizzoli /osteosarcoma-2 protocol: an updated report. J Clin Oncol 2000;18:4016-27
  5. Meyers PA, Gorlick R, Heller G, Casper E, Lane J, Huvos AG, et al. Intensification of preoperative chemotherapy for osteogenic sarcoma: results of the Memorial Sloan-Kettering (T12) protocol. J Clin Oncol 1998;16:2452-8
  6. Petrilli AS, de Camargo B, Filho VO, Bruniera P, Brunetto AL, Jesus-Garcia R, et al. Results of the Brazilian Osteosarcoma Treatment Group Studies III and IV: prognostic factors and impact on survival. J Clin Oncol 2006;24:1161-8
  7. Enneking WF, Dunham W, Gebhardt MC, Malawar M, Pritchard DJ. A system for the functional evaluation of reconstructive procedures after surgical treatment of tumors of the musculoskeletal system. Clin Orthop Relat Res 1993;(286):241-6
  8. Bacci G, Ferrari S, Mercuri M, Longhi A, Capanna R, Tienghi A, et al. Neoadjuvant chemotherapy for extremity osteosarcoma-preliminary results of the Rizzoli’s 4th study. Acta Oncol 1998;37:41-8
  9. Wilkins RM, Cullen JW, Odom L, Jamroz BA, Cullen PM, Fink K, et al. Superior survival in treatment of primary nonmetastatic pediatric osteosarcoma of the extremity. Ann Surg Oncol 2003;10:498-507
  10. Scully SP, Ghert MA, Zurakowski D, Thompson RC, Gebhardt MC. Pathologic fracture in osteosarcoma: prognostic importance and treatment implications. J Bone Joint Surg [Am] 2002;84:49-57
  11. Kaste SC, Fuller CE, Saharia A, Neel MD, Rao BN, Daw NC. Pediatric surface osteosarcoma: clinical, pathologic, and radiologic features. Pediatr Blood Cancer 2006;47:152-62
  12. Okada K, Frassica FJ, Sim